{"id":18693,"date":"2021-08-05T10:09:10","date_gmt":"2021-08-05T08:09:10","guid":{"rendered":"https:\/\/idibell.cat\/?p=18693"},"modified":"2023-10-06T15:31:41","modified_gmt":"2023-10-06T13:31:41","slug":"nous-avencos-en-la-caracteritzacio-de-la-malalta-minoritaria-limfangioleiomiomatosis","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2021\/08\/nous-avencos-en-la-caracteritzacio-de-la-malalta-minoritaria-limfangioleiomiomatosis\/","title":{"rendered":"Nous aven\u00e7os en la caracteritzaci\u00f3 de la malalta minorit\u00e0ria Limfangioleiomiomatosis"},"content":{"rendered":"<p>La <strong>Limfangioleiomiomatosi<\/strong> (LAM) \u00e9s una malaltia minorit\u00e0ria que gaireb\u00e9 exclusivament afecta les dones. Aquesta malaltia es caracteritza per la proliferaci\u00f3 de c\u00e8l\u00b7lules epitelials i fusiformes que poden acabar danyat el teixit pulmonar, i incl\u00fas, en els casos m\u00e9s severs, provocar insufici\u00e8ncia respirat\u00f2ria. Emp\u00edricament, la LAM es defineix com una neopl\u00e0sia de baix grau amb capacitat metast\u00e0tica, ja que les c\u00e8l\u00b7lules patol\u00f2giques <strong>presenten trets fonamentals del c\u00e0ncer<\/strong> com: la proliferaci\u00f3 continuada, la resist\u00e8ncia a mecanismes d\u2019inducci\u00f3 de mort, la migraci\u00f3 i invasi\u00f3 de teixits i la evasi\u00f3 del sistema immunitari.<\/p>\n<p>Un equip liderat pel <strong>Dr. Miquel \u00c0ngel Pujana<\/strong>, cap del grup de recerca en C\u00e0ncer de Mama del programa Oncobell i ProCURE de l\u2019<a href=\"https:\/\/idibell.cat\/recerca\/area-de-cancer\/programa-de-mecanismes-molleculars-i-terapia-experimental-en-oncologia-oncobell\/cancer-de-mama\/\">IDIBELL<\/a> i de l&#8217;ICO, ha utilitzat els perfils d&#8217;expressi\u00f3 g\u00e8nica i proteica de les c\u00e8l\u00b7lules i teixits de LAM per <strong>determinar-ne les caracter\u00edstiques biol\u00f2giques que explicarien l\u2019alta heterogene\u00eftat inter- i intra-pacients<\/strong>. L\u2019estudi ha identificat similituds amb el c\u00e0ncer que indiquen el possible origen de LAM i senyalen biomarcadors de progressi\u00f3 de la malaltia.<\/p>\n<p>L&#8217;estudi publicat a la revista <em>Molecular <\/em><a href=\"https:\/\/mcr.aacrjournals.org\/content\/early\/2021\/07\/26\/1541-7786.MCR-21-0220\"><em>Cancer Research<\/em><\/a> demostra que els diferents subtipus de c\u00e8l\u00b7lules de LAM difereixen en perfils d&#8217;expressi\u00f3 g\u00e8nica relacionats amb <strong>senyalitzaci\u00f3 hormonal, metabolisme, proliferaci\u00f3 i diferenciaci\u00f3<\/strong>. Els investigadors han identificat com a m\u00ednim dos subtipus de c\u00e8l\u00b7lules patol\u00f2giques en els pulmons de les pacients amb LAM. \u201c<em>\u00c9s possible que aquets subtipus responguin de forma diferent al tractament est\u00e0ndard de la malaltia, la rapamicina<\/em> -comenta el <strong>Dr. Pujana<\/strong>-, <em>no obstant, es requereixen estudis addicionals per corroborar-ho<\/em>\u201d.<\/p>\n<p>Per altra banda, les diferents an\u00e0lisis apunten a que la gran variabilitat entre pacients podria ser deguda a com el <strong>sistema immunitari<\/strong> es relaciona amb la malaltia. En l\u2019estudi han identificat dos tipus de lesions pulmonars que es diferencien per factors immunitaris, aix\u00f2, segons el Dr. Pujana, podria tamb\u00e9 influir en la resposta al tractament de les pacients. No obstant, altre cop, caldrien m\u00e9s an\u00e0lisis per confirmar-ho.<\/p>\n<p>Els primers autors de l\u2019estudi s\u00f3n els estudiants de doctorat IDIBELL <strong>Roderic Esp\u00edn<\/strong> i <strong>Alexandra Baiges<\/strong>. En aquest treball hi han participat diversos\/es investigadors\/es i responsables cl\u00ednics del LAM, referents en l\u2019Hospital Universitari de Bellvitge, l\u2019Hospital Universitari de la Vall d\u2019Hebron, l\u2019Hospital Universitari de La Princesa, l\u2019Hospital Universitari Cl\u00ednica Puerta del Hierro, l\u2019Hospital Universitari Virgen del Roc\u00edo, l\u2019Hospital Universitari d\u2019Henares, el centre de recerca en malaltia pulmonar intersticial (ILD) del St. Antonius Hospital dels Pa\u00efsos Baixos, i el The National Heart, Lung, and Blood Institute (NHLBI) dels Estats Units. En l\u2019estudi han participat tamb\u00e9 investigadors d\u2019altres programes IDIBELL: Dra. Mar\u00eda Molina-Molina (Programa de Malalties Cardiovasculars, Respirat\u00f2ries, Sist\u00e8miques i d\u2019Envelliment Cel\u00b7lular), Drs. Anna Villar-Piqu\u00e9, Daniela Diaz-Lucena, i Mireya Plass (Programa de Medicina Regenerativa, P-CMRC).<\/p>\n<p>Aquest treball ha estat possible gr\u00e0cies a la participaci\u00f3 de les pacients LAM i el suport obtingut pel conveni de col\u00b7laboraci\u00f3 establert entre l\u2019ICO, l\u2019IDIBELL i l\u2019Associaci\u00f3 Espanyola de LAM (AELAM; <a href=\"https:\/\/www.aelam.org\/\">https:\/\/www.aelam.org\/<\/a>).<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><em>L\u2019Institut d&#8217;Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l&#8217;Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l&#8217;Institut Catal\u00e0 de la Salut, l&#8217;Institut Catal\u00e0 d&#8217;Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n<p><em>L\u2019IDIBELL \u00e9s membre del Campus d&#8217;Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L&#8217;any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Un equip de l\u2019IDIBELL i de l\u2019ICO, a trav\u00e9s de l\u2019an\u00e0lisi de l\u2019expressi\u00f3 de gens i prote\u00efnes en aquesta malaltia, n\u2019ha determinat les caracter\u00edstiques biol\u00f2giques que explicarien l\u2019alta heterogene\u00eftat i les similituds moleculars amb el c\u00e0ncer.<\/p>\n","protected":false},"author":8,"featured_media":18694,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[332,390,447,452],"tags":[],"class_list":["post-18693","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-cancer-de-mama","category-p-de-mecanismes-molelculars-i-terapia-experimental-en-oncologia-oncobell","category-procure"],"publishpress_future_action":{"enabled":false,"date":"2025-01-03 02:32:12","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/18693","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=18693"}],"version-history":[{"count":3,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/18693\/revisions"}],"predecessor-version":[{"id":24269,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/18693\/revisions\/24269"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/18694"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=18693"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=18693"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=18693"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}